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Abstract Site-directed mutagenesis was used to map the ligand-
binding surface of the type II transforming growth factor-L
receptor extracellular domain (TLRII-ECD). Two putative
ligand-binding sites were probed, the first being a predicted
hydrophobic patch, the second being the finger 1 surface loop.
Nine residues were mutated in the context of full-length TLRII
and the effect of these mutations on ligand-binding and receptor
signaling was analyzed. Complementary information was
obtained by examining ‘natural’ evolutionary TLRII mutations.
Together, the results indicate that residues within the finger 1
region, but not the hydrophobic patch, of the TLRII-ECD are
required for productive ligand-binding. We conclude that,
surprisingly, the ECDs of TLRII and type II activin receptor
utilize distinct interacting surfaces for binding their respective
ligands. ß 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Transforming growth factor-L (TGF-L) is a member of a
family of dimeric polypeptides that includes bone morphoge-
netic proteins and activins [1,2]. The signaling pathways that
are stimulated by TGF-L regulate many critical cellular pro-
cesses such as cell growth, di¡erentiation, extracellular matrix
deposition and immune function [1,2]. Most biological e¡ects
of TGF-L are mediated by the type I (TLRI) and type II
(TLRII) cell surface receptors, which are both required for
TGF-L signaling [3,4]. Previous studies on TGF-L signaling
[5,6,7^10] have suggested that TLRII, a constitutively acti-
vated kinase, is the primary sensor for the presence of
TGF-L and that, after the initial ligand-binding event, the
TGF-L/TLRII complex recruits and phosphorylates TLRI,
which then propagates a signal to downstream substrates.
Dissecting the structural basis for the high a⁄nity interaction
between TGF-L and TLRII is of fundamental importance to-
wards understanding the initial molecular events in the acti-
vation of TGF-L signaling pathways. It will also provide use-
ful molecular design strategies towards modulating the many
important e¡ects of TGF-L.
In two previous studies, using a scanning-deletion mutagen-
esis approach combined with a homology model of the TLRII
extracellular domain (TLRII-ECD), we delineated the core
ligand-binding domain of TLRII and identi¢ed two regions
within this core domain as putative ligand-binding sites
[11,12]. The ¢rst region is an extended hydrophobic patch
on the concave face of the ECD while the second site is the
¢nger 1 surface loop of the ECD. Mutational analysis of a
hydrophobic patch on the mouse type II activin receptor (Ac-
tRII)-ECD that is similar to the one on the TLRII-ECD dem-
onstrated that it forms a critical ligand-binding surface for
activin and inhibin, supporting the idea that this region may
form a ligand-binding site on the TLRII-ECD [13]. To verify
the function of the hydrophobic patch and ¢nger 1 regions on
the TLRII-ECD, we have now analyzed the e¡ect of introduc-
ing single-residue mutations into these sites on ligand-binding
as well as receptor signaling. As a complement to this site-
directed mutational approach, we also examined the ‘natural’
mutagenesis of TLRII that occurred during evolution by
aligning TLRII-ECD sequences from various species. Taken
together, our results demonstrate that residues within the ¢n-
ger 1 region, but not the hydrophobic patch, of the TLRII-
ECD are important for productive ligand-binding, thereby
demonstrating that the ECDs of TLRII and ActRII utilize
distinct interacting surfaces for binding their respective li-
gands.
2. Materials and methods
2.1. Mutagenesis
Mutagenesis of the human TLRII coding region subcloned in
pCDNA-3 (Invitrogen) was done by site-directed mutagenesis [14].
Primers used in this analysis are as follows: 5P and 3P common prim-
ers are, respectively, II-1: 5P-AAGCTTCACCATGGAGGCGGCG,
and AS.1: 5P-TTGTGGTTGATGTTGTTGG. Mutagenic primers
are as follows, with only the forward primer shown, the reverse primer
being its exact complement (names correspond to the position of the
mutated amino acid on the human cDNA):
C67A.gen: 5P-GCAGTTGCTCATGGCGGATTTCTGGTTG, C-
71A.gen: 5P-GCATGAGCAACGCCAGCATCACC, V85A.gen: 5P-
GGAAGTCTGTGCGGCTGTATGG, V87A.gen: 5P-GTCTGTGT-
GGCTGCATGGAGAAAG, L97A.gen: 5P-CGAGAACATAACAG-
CAGAGACAGTTTG, E98A.gen: 5P-AGAACATAACACTAGCG-
ACAGTTTGCC, E98Q.gen: 5P-AGAACATAACACTACAGACAG-
TTTGCC, V100A.gen: 5P-AACACTAGAGACAGCTTGCCATGA-
CC, F133A.gen: 5P-CCTGGTGAGACTGCCTTCATGTGTTCC,
M135A.gen: 5P-GGTGAGACTTTCTTCGCGTGTTCCTGTAGC.
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2.2. Cell culture and transfection
HEK 293 cells were maintained in Dulbecco’s modi¢ed Eagle’s
media (DMEM; Gibco) supplemented with 10% fetal bovine serum
(FBS; Gibco). All transfections were done in six- or 12-well plates
using the SuperFect reagent (Qiagen) according to the manufacturer’s
protocol unless otherwise speci¢ed.
2.3. Surface expression
HEK 293 cells were seeded in six-well dishes and transfected using
2 Wg of DNA and 5 Wl of SuperFect reagent according to the manu-
facturer’s protocol. 48 h after transfection the cells were re-suspended
in cold DMEM^10% FBS for 30 min at 4‡C. Cells were then incu-
bated for 1 h at 4‡C in the presence of an anti-TLRII antibody (RpD
Systems) directed against the ECD. After washing in cold DMEM^
10% FBS, the cells were incubated for 1 h with an FITC conjugate
goat anti-rabbit IgG (Sigma) diluted 1/100. Cells were then washed in
cold DMEM^10% FBS and analyzed by £ow cytometry on an EPI-
CS0 XL-MCS (Beckman-Coulter0).
2.4. Cross-linking ligand-binding assay
48 h after transfection, the cells were incubated with 100 pM of
[I125]TGF-L1 for 2^3 h. After washing with D-PBS, the receptor-
bound ligand was cross-linked with BS3 (Pierce) for 5 min followed by
an additional 5 min in 100 mM glycine to stop the reaction. Total
protein was then extracted in solubilization bu¡er (1% Triton X-100,
10% glycerol, 20 mM Tris^HCl pH 7.4, 1 mM EDTA and PMSF) at
4‡C for 30 min.
2.5. Direct ligand-binding assay
HEK 293 cells were transfected in triplicate as previously described.
48 h after transfection the cells were incubated for 2 h on ice with 100
pM [I125]TGF-L1 with or without 10 nM of unlabeled TGF-L1 as
speci¢c competitor in the binding bu¡er (D-PBS, 0.1% BSA). Cells
were washed for 2^3 min with 500 Wl of binding bu¡er, then acid-
washed (150 mM NaCl, 0.1% acetic acid) twice for 2 min to recover
bound ligand. The two acid washes were pooled and counted on a
gamma counter. For each mutant tested, the counts obtained from the
competed samples were subtracted from the total counts (non-com-
peted) to determine speci¢c binding. In the case of the fast washing
procedure, cells were washed for less than 5 s with 500 Wl of binding
bu¡er.
2.6. Smad2 phosphorylation signaling assay
HEK 293 cells were transiently cotransfected in triplicate with Flag-
Smad2 (generously provided by Dr. L. Attisano, University of To-
ronto, Toronto, Canada) and the indicated TLRII mutant plasmids in
a 1:1 ratio using the SuperFect reagent. Total DNA was kept con-
stant by adding pCDNA-3. 24 h after transfection, the cells were
incubated in DMEM without serum (DMEM-0) for 2^4 h, and
then incubated with or without 400 pM of TGF-L1 for 15^20 h. Cells
were then washed twice with PBS and the protein was extracted in
solubilization bu¡er at 4‡C for 30 min. The amount of protein was
quanti¢ed using BCA reagent (Pierce) and 3 Wg of protein from each
sample was loaded onto 10% SDS^polyacrylamide gels. The protein
was transferred onto Immobilon-P membranes (Millipore), which
were rinsed in water for 2 min, then in methanol for 2 min, and
air-dried. The dry membranes were then incubated with the appropri-
ate primary antibody diluted in 5% skim milk/TBS overnight at 4‡C.
The membranes were then washed 4U15 min with TBS-Tween 0.05%
and incubated with horseradish peroxidase-conjugated anti-rabbit or
anti-mouse IgG secondary antibody (Jackson) at 1/10 000 dilution in
5% skim milk/TBS at room temperature for 1 h. After extensive wash-
ing, the signals were revealed with ECL detection reagents (Renais-
sance-ECL kit, NEN). The anti-phospho-Smad2 primary antibody
(Geneka Biotechnology) was used at a 1/1000 dilution, the M2 anti-
Flag antibody (Kodak) was used at a 1/5000 dilution and the anti-
hTLRII-ECD antibody (2379; produced in our laboratory) was used
at a 1/1000 dilution. The same membranes were stripped and re-
probed to monitor expression levels of the transfected plasmids.
2.7. Statistics
Data were analyzed by one-way analysis of variance using Ps 0.05
as signi¢cance criterion. Post-hoc analysis relied on Dunnett’s multi-
ple comparison test using the Prism software (GraphPad Software
Inc.).
3. Results
3.1. Design of TLRII mutants
We have previously delineated the core ligand-binding do-
main of the full-length human TLRII using a scanning-dele-
tion mutagenesis approach [11]. We then extended the scan-
ning-deletion mutagenesis analysis to within the core ligand-
binding domain itself, and rationalized the results using a
homology model of the TLRII-ECD structure that was based
on the crystal structure of the ECD of the mouse ActRII [12].
In that study, a solvent-exposed hydrophobic patch lining
the concave face of the TLRII-ECD modeled structure was
identi¢ed as a potential protein-binding interface and was
suggested to be a putative ligand-binding site [12]. A similar
hydrophobic patch exists on the ActRII-ECD structure [15].
Mutational analysis of mouse ActRII demonstrated that three
residues, F42, W60, and F83 from this hydrophobic site, form
a critical binding surface required for functional interactions
with both activin and inhibin [13]. In this report, in order to
verify whether the corresponding hydrophobic site on TLRII-
ECD is implicated in binding the TGF-L ligand, we individ-
ually mutated six hydrophobic residues, V85, V87, L97, V100,
F133, and M135, to alanine in the context of the full-length
human TLRII. Residues V85 and M135 of human TLRII
correspond to ligand-binding site residues F42 and F83 of
mouse ActRII, respectively. In addition, the role of a nega-
tively charged residue, E98, which is adjacent to this hydro-
phobic patch, was explored by generating two mutants, E98Q
and E98A. The search for a negatively charged residue on
TLRII that may be involved in ligand-binding was motivated
by the ¢nding that a positively charged residue, R94, of the
TGF-L1 ligand is important for binding to TLRII [16]. Since
the side chains of all these mutated residues are predicted to
be exposed at the protein surface, the risk of introducing sig-
ni¢cant conformational changes upon mutation is low.
Out of the ¢ve structurally variable regions identi¢ed be-
tween the TLRII-ECD model and ActRII-ECD structure,
three represent insertions in TLRII-ECD relative to ActRII-
ECD. Our previous scanning-deletion mutagenesis results in-
dicated that two of these larger surface loops in TLRII-ECD
can be partially deleted without a¡ecting TGF-L-binding, and
that only one of them, the so-called ¢nger 1, might form a
Fig. 1. Surface expression of TLRII mutants. Transiently transfected
HEK 293 cells were incubated with an antibody directed against the
TLRII-ECD and detected by £ow cytometry analysis with an FITC-
conjugated secondary antibody (see Section 2). Histograms show the
mean £uorescence values calculated from at least three independent
experiments.
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binding interface with the ligand [12]. Finger 1 appears as a
unique, distinctive structural feature of TLRII in that it con-
tains four additional cysteine residues outside the canonical
pattern of cysteine residues characteristic of the ‘three-¢nger
toxin’ fold. Knowledge-based modeling predicted that the ¢n-
ger 1 of TLRII-ECD would contain two disul¢de bonds, C54^
C71 and C61^C67 [12]. Two mutants were thus generated,
C67A and C71A, in order to investigate the role of these
disul¢de bonds in constraining a putative bioactive conforma-
tion adopted by the ¢nger 1 of TLRII. Because of the signi¢-
cant sequence variability of the ¢nger 1 in the ‘three-¢nger
toxin’ fold family [15], these mutations are expected not to
disrupt the fold of the ECD structure.
3.2. Surface expression of TLRII mutants
We examined the level of expression of the 10 TLRII point
mutants at the surface of transiently transfected HEK 293
cells by £ow cytometry analysis using an ECD-directed anti-
body (Fig. 1). HEK 293 cells were chosen because they ex-
press very low levels of endogenous TGF-L receptors and
because they are transfected with high e⁄ciency. Seven of
the receptor mutants were expressed at levels comparable
with that of the wild-type receptor. The remaining three mu-
tants, C67A, C71A, and L97A, displayed approximately half
of the wild-type TLRII expression level. These results indicate
that the TLRII mutants are expressed and transported to the
cell surface, which suggests that no major conformational
alteration of the ECD structure as a whole (i.e. unfolding or
misfolding) was introduced upon mutation.
3.3. Ligand-binding by TLRII mutants
We evaluated the ligand-binding properties of the TLRII
mutants in HEK 293 cells by covalently cross-linking the ra-
diolabeled TGF-L1 ligand to the mutant receptors. We also
veri¢ed ligand-binding in a direct binding assay using radio-
labeled and unlabeled TGF-L1 (see Section 2). As shown in
Fig. 2, similar levels of cross-linked ligand^receptor complexes
were detected for the wild-type receptor and seven TLRII
mutants targeting residues on the concave face of the ECD:
V85A, V87A, E98A, E98Q, V100A, F133A, and M135A. No
cross-linked receptors were detected when the vector alone
was transfected, con¢rming the low level of endogenous
TLRII. These results indicate that the TGF-L-binding site
does not correspond to the hydrophobic patch on the concave
side of TLRII-ECD, and that the acidic residue E98 is not
engaged in speci¢c electrostatic interactions with the ligand.
Importantly, since mutation of residues V85 and M135, which
correspond to the activin- and inhibin-binding site residues
F42 and F83 of ActRII-ECD, did not a¡ect TGF-L-binding,
our data indicate that TLRII and ActRII utilize distinct, non-
overlapping surfaces for binding their respective ligands.
Three TLRII mutants could not be cross-linked to
[I125]TGF-L1 (Fig. 2). They correspond to the alanine muta-
tion of two cysteine residues, C67 and C71 from ¢nger 1, and
of a hydrophobic residue, L97, from the concave face of the
ECD. These three mutants are expressed at the cell surface at
approximately half the level of the wild-type TLRII (Fig. 1),
which is well within the detection range of the cross-linking
assay. Therefore, although these three TLRII mutants are
present at the surface of the HEK 293 cells, they cannot be
e⁄ciently cross-linked to the ligand, presumably due to im-
paired ligand^receptor interactions upon mutation.
To verify this lack of ligand-binding, we employed a di¡er-
ent assay that does not involve covalent ligand^receptor cross-
linking. Since cross-linking reactions are highly dependent on
the proximity of the reacting groups, ligand-binding might not
Fig. 2. Ligand cross-linking to TLRII mutants. HEK 293 cells were
transiently transfected with wild-type or mutant TLRIIs followed by
cross-linking to [I125]TGF-L1. Labeled receptors were resolved on
4^12% gradient gels and exposed to phosphorimager screens. Mu-
tants are labeled in the respective lanes. M: molecular weight
marker. The arrow indicates the TLRII band.
Fig. 3. Direct ligand-binding to TLRII mutants. Transiently trans-
fected HEK 293 cells were incubated with [I125]TGF-L1 in the pres-
ence (competed) or absence of 100-fold excess of unlabeled TGF-L1.
Surface-bound ligand was recovered by two acidic washing steps
after removal of the excess ligand by (a) a regular washing protocol
or (b) a fast washing protocol (see Section 2). Histograms show the
mean value calculated from three independent experiments. Data
are expressed as speci¢c counts obtained for the wild-type TLRII,
and were calculated by subtracting counts from competed samples
from counts from non-competed sample.
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be detected due to subtle changes in the positioning of the
reacting groups that could occur upon mutation. Wild-type
and selected TLRII mutants (C67A, C71A, L97A, and
F133A) were transfected in HEK 293 cells and incubated in
the presence of [I125]TGF-L1 with or without a 100-fold excess
of unlabeled TGF-L1 competitor. After washing o¡ unbound
ligand, receptor-bound ligand was recovered. The counts from
samples with competitor were subtracted from the counts
from samples without competitor to obtain speci¢c binding.
As expected (see Fig. 3a) the level of speci¢c binding obtained
with mutant F133A was similar to the level obtained with the
wild-type receptor. On the other hand, the level of speci¢c
Fig. 4. Smad2 phosphorylation signaling by TLRII mutants. Wild-type or mutant TLRII was cotransfected with Flag-tagged Smad2 and the
cells treated (+) or not (3) with TGF-L1. Phosphorylated Smad2 was revealed by Western blot with and anti-phospho-Smad2 antibody (PO4-
Smad2). Expression level of Flag-Smad2 was detected with and anti-Flag antibody and is shown on the middle panel (Flag). Expression of
transfected receptors was detected with an anti-TLRII-ECD antibody (TLRII) and is shown on the bottom panel.
Fig. 5. Mapping of the mutagenesis data onto the modeled structure of TLRII-ECD [12] (upper panels) and crystal structure of ActRII-ECD
[15] (lower panels). a: Ribbon diagrams of the ECD structures, with cysteine side chains displayed as ball and stick representation with yellow
atoms. The orientation of the two ECDs corresponds to their structural alignment. b: Molecular surface representation of the ECD structures
displayed with the convex side in front in an orientation similar to that shown in (a), and (c) with the concave side in front corresponding to
V180‡ rotation relative to the orientation in (a) and (b). The molecular surface patches associated with the side chains of TLRII residues mu-
tated to alanine in this study and of ActRII residues mutated to alanine in [13] are color-coded. Red surface areas correspond to side chains
identi¢ed as being required for a functional interaction with the respective ligands of each receptor, and blue coloring corresponds to side
chains not required for functional ligand-binding. Surface areas corresponding to individual three-residue deletions within the core ligand-bind-
ing domain of TLRII that were shown not to alter ligand-binding [12] are colored in light blue.
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binding for mutants C67A, C71A, and L97A did not di¡er
signi¢cantly from the pCDNA-3 control, indicating that the
interaction between TGF-L1 and these receptor mutants could
not be detected. If the ligand has a lower a⁄nity for these
mutants due to a faster dissociation rate, bound ligand might
dissociate from the receptor during the washing step and no
interaction would be detected. To further clarify this issue, we
repeated the experiment with a very fast washing step before
the recovery of the bound ligand (see Section 2). When using
this approach, speci¢c ligand-binding to mutant F133A re-
mained similar to that of the wild-type receptor, while speci¢c
binding to both C67A and C71A mutants was still not sig-
ni¢cantly di¡erent from the pCDNA-3 control (Fig. 3b).
These results remain consistent with those from the covalent
ligand^receptor cross-linking assay (Fig. 2). However, we ob-
served a signi¢cant amount of bound ligand for the L97A
mutant (V230% relative to the pCDNA-3 control and
V65% relative to the wild-type receptor), indicating that
TGF-L1 binds to the L97A receptor mutant, but that it likely
dissociates from it at a fast rate.
3.4. TGF-L signaling by TLRII mutants
It is currently accepted that binding of TGF-L to TLRII
leads to recruitment and phosphorylation of TLRI [5,6], which
then triggers several signaling pathways by activating down-
stream targets such as the Smad family of proteins [17^19]. It
is therefore conceivable that any signi¢cant decrease in li-
gand^TLRII binding a⁄nity (e.g. attainable here by point
mutations of the receptor) would impair the TGF-L signaling
function. We tested the ability of TLRII mutants to mediate a
functional TGF-L response in intact cells by using a Smad2
phosphorylation assay. The TLRII mutants were transiently
cotransfected with Flag-Smad2 in HEK 293 cells. As demon-
strated by the receptor^ligand cross-linking experiments (Fig.
2), these cells express very low levels of endogenous TGF-L
receptors; however, the amount of endogenous TLRI is su⁄-
cient to support ligand-dependent phosphorylation of trans-
fected Smad2 in the presence of cotransfected TLRII. The
level of expression of the TLRII mutants and the level of
Smad2 phosphorylation achieved by those mutants were
monitored by Western blot analysis. As shown in Fig. 4, li-
gand-stimulated Smad2 phosphorylation was detected for
nine out of the 10 TLRII mutants investigated, indicating
that these are functional receptor mutants that are able to
participate in signaling competent heteromeric receptor com-
plexes in the presence of the TGF-L ligand. C71A was the
only inactive mutant in the Smad2 phosphorylation assay.
Except for the C67A mutant which displayed ligand-depen-
dent signaling, but lacked detectable ligand-binding, the re-
sults obtained from the signaling assay were in agreement
with the ligand-binding data (Figs. 2 and 3). Our combined
results indicate that the side chains of seven residues within
the hydrophobic patch on the concave side of the TLRII-ECD
are not important for ligand-binding, and are not required for
ligand-dependent signaling towards the intracellular down-
stream target, Smad2. Residue C71 in the ¢nger 1 of the
ECD is required for both ligand-binding and signaling. The
disagreement between the signaling and ligand-binding assays
for the C67A mutant may result from this mutant-binding
ligand with a very fast dissociation rate, such that radioli-
gand-binding and cross-linking were undetectable, while re-
ceptor signaling was ligand-dependent.
4. Discussion
In order to map the TGF-L-binding site of TLRII, we gen-
erated a set of single-residue mutations within the ECD of the
full-length human receptor. The design of these mutants was
based on previous data that we obtained by combining scan-
ning-deletion mutagenesis of TLRII with a homology model
of the TLRII-ECD structure [12]. In that report, two regions
on TLRII-ECD were identi¢ed as putative binding sites (see
also Section 3.1). The ¢rst one is an extended hydrophobic
patch on the concave face of the ECD. The second region is
the ¢nger 1 surface loop of the ECD. To investigate these two
regions further, we introduced 10 single-residue mutations
targeting nine residues into full-length TLRII (Fig. 5). The
resulting mutants were tested for their ability to bind the
TGF-L1 ligand as well as to support a functional TGF-L
response in intact cells.
Fig. 6. Sequence alignment of the ECDs from TLRII species homologues. h ^ human, m ^ mouse, r ^ rat, p ^ pig, c ^ chicken, x ^ X. laevis.
The sequence of mouse ActRII ECD is also aligned. Cysteine residues are shown in bold. Predicted disul¢des in the ¢nger 1 of TLRII-ECD
are indicated. Identical residues across the TLRII-ECD alignment are highlighted on a yellow background. TLRII residues identi¢ed in this
study as being required for functional binding to TGF-L, and ActRII residues identi¢ed in [13] as being critical for functional binding to acti-
vin are shown on a red background. The other residues investigated by mutagenesis, and which have no e¡ect on the functional binding of the
respective ligands, are shown on a blue background. ‘Natural mutations’ within the TLRII species homologues that correspond to positions
mutated in this study are highlighted on a violet background. Asterisks indicate identical acidic residues across the TLRII-ECD alignment.
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Seven mutations that were introduced on the hydrophobic
surface on the concave side of the ECD, V85A, V87A, E98A,
E98Q, V100A, F133A, and M135A, did not a¡ect ligand-
binding, as shown independently by covalent ligand^receptor
cross-linking and direct binding assays (Figs. 2 and 3).
Although ligand^receptor cross-linking was not detected for
the L97A mutant, a fast washing procedure applied in the
direct binding assay revealed signi¢cant ligand-binding to
this mutant (Fig. 3b). Furthermore, all of these eight receptor
mutants were able to support a ligand-dependent functional
response as demonstrated in a Smad2 phosphorylation signal-
ing assay (Fig. 4). Taken together, these data demonstrate
that the hydrophobic patch on the concave side of the ECD
does not form a critical binding surface required for function-
al interactions with TGF-L. This is also consistent with our
previous results showing that three-residue deletions intro-
duced in two surface loops that are adjacent to this region
do not alter ligand-binding signi¢cantly (Fig. 5c). In addition,
the data obtained for the mutants E98A and E98Q demon-
strate that residue E98, which is located near this hydrophobic
patch, does not represent the direct binding partner for the
critical residue R94 of the TGF-L1 ligand [16].
Structural studies have shown the existence of a similar
hydrophobic surface on the concave side of the ECD of Ac-
tRII [15]. A mutational analysis of the full-length mouse Ac-
tRII, in which 19 solvent-exposed residues of the ECD were
individually mutated to alanine, has recently been published
[13]. In that study, three residues, F42, W60, and F83, that
cluster on the hydrophobic surface on the concave side of
ActRII-ECD (Fig. 5), were identi¢ed as being required for
both activin- and inhibin-binding and for a functional activin
response in intact cells. Residues F42 and F83 correspond to
the human TLRII residues V85 and M135 that we mutated in
this study to alanine, with no signi¢cant e¡ect on ligand-bind-
ing and signaling properties of the receptor. Hence, it appears
that despite the predicted similarities in fold topology, the
ECDs of TLRII and ActRII utilize distinct interacting surfa-
ces for binding their respective ligands (Fig. 5).
A striking di¡erence between TLRII-ECD and ActRII-
ECD is a surface loop called ¢nger 1, which contains an in-
sertion of six residues as well as four additional cysteine res-
idues relative to ActRII. Homology modeling of the TLRII-
ECD structure predicted formation of two disul¢de bonds in
¢nger 1 [12], C54^C71 at the loop-anchor positions, and C61^
C67 in the middle of the loop (Fig. 5a). In addition to these
unique structural features, we previously found that three-res-
idue deletions in ¢nger 1 abolish ligand-binding [12]. We hy-
pothesized that ¢nger 1 could be implicated in functional in-
teractions with TGF-L, which prompted us to generate in this
study two TLRII mutants, C67A and C71A, each predicted to
have a disruption of one of the two disul¢de bonds in ¢nger 1
of the ECD. The mutation of residue C71 to alanine abolished
both the ligand-binding and signaling capabilities of TLRII.
In contrast, mutant C67A exhibited a positive functional re-
sponse to TGF-L in the Smad2 phosphorylation assay,
although we were unable to detect ligand-binding to this mu-
tant. Thus, it appears that the disruption of the predicted
disul¢de bond C54^C71 at the anchor of ¢nger 1 has a
more pronounced e¡ect than disruption of the predicted di-
sul¢de bond C61^C67 within the ¢nger 1 itself. In the mod-
eled structure of TLRII-ECD, the disul¢de C54^C71 is sol-
vent-exposed (Fig. 5b), and could directly interact with the
ligand as part of a larger binding surface on the convex face
of the ECD. Alanine mutation of several residues on the con-
vex face of ActRII-ECD has been shown to have no e¡ect on
activin- and inhibin-binding, and activin-dependent signaling
of ActRII [13]. This further supports the existence of distinct
ligand-binding sites on TLRII-ECD and ActRII-ECD (Fig.
5). However, it is possible that the disul¢de bonds in ¢nger
1 constrain a bioactive conformation of this surface loop, with
a critical role played by the predicted anchor disul¢de C54^
C71. Further biochemical studies complemented by the exper-
imental determination of the TLRII-ECD structure in the
presence and absence of the ligand will be needed to clarify
these issues.
Sequence analysis shows a high degree of conservation be-
tween the ECDs of various mammalian TLRIIs, and a some-
what lower sequence identity relative to the avian TLRII-ECD
(Fig. 6). During the progress of this work, a TLRII from
Xenopus laevis has been isolated and characterized [20].
Although this receptor displays only 67% amino acid similar-
ity with human TLRII in the ECD portion, it binds TGF-L
and supports a TGF-L-mediated response in HepG2 cells. A
sequence alignment that includes not only the various mam-
malian and avian TLRII-ECD sequences, but also the se-
quence of the more distant yet functional X. laevis TLRII-
ECD, would reveal the ‘natural’ mutagenesis of TLRII that
occurred during evolution, and thus complement our site-di-
rected mutational analysis data. As shown in Fig. 6, the seven
residues of human TLRII, which belong to the hydrophobic
patch on the concave face of the ECD, and which we found
not to play a functional role, are also not identical in the
sequences of the six TLRII species homologues. Residues
V87, E98, V100, F133, and M135 in the human receptor cor-
respond to isoleucine, serine, arginine, leucine, and threonine,
respectively, in the X. laevis TLRII. Further comparison
shows that human TLRII residues V85, V100, and F133 are
replaced by alanine, isoleucine, and methionine, respectively,
in the avian receptor, and that residue L97 aligns to an iso-
leucine in the porcine receptor. It is also interesting to note
that residue H102 that was not mutated in this study, but
which corresponds to the activin-binding site residue W60 of
ActRII [13], is replaced by an aspartate in the porcine recep-
tor, further supporting our ¢nding of di¡erent ligand-binding
sites on TLRII-ECD and ActRII-ECD. In contrast, the four
cysteines in the ¢nger 1 of the ECD are preserved in all six
species homologues of TLRII. It appears that the sequence
conservation is higher around the predicted disul¢de C54^
C71 than in the vicinity of the predicted disul¢de C61^C67.
This agrees with our ¢nding that the C71A mutant receptor is
functionally non-responsive to TGF-L whereas the C67A mu-
tation retains the ligand-dependent signaling capability of the
receptor. Finally, ¢ve acidic residues, D55, E78, E82, E142,
and D145, of human TLRII are identical across the sequence
alignment. Some of these residues may be engaged in speci¢c
electrostatic interactions (e.g. salt bridge or hydrogen bond)
with the ligand, and more speci¢cally with the critical TGF-L1
residue R94 [16]. A possible candidate for this interaction is
D55, which is adjacent to the functionally important, pre-
dicted disul¢de C54^C71.
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